Showing results (71-80 of 79) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Nature|March 15, 2023
Lactate regulates cell cycle by remodelling the anaphase promoting complexWeihai Liu, Yun Wang, Luiz H M Bozi, et al.Molecular Cell|August 22, 2025
Expanding the druggable zinc-finger proteome defines properties of drug-induced degradationMikołaj Słabicki, Jiho Park, Radosław P Nowak, et al.Cell|December 4, 2020
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader DevelopmentKatherine A Donovan, Fleur M Ferguson, Jonathan W Bushman, et al.Cell Host & Microbe|December 15, 2015
Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus BuddingShashank Tripathi, Marie O Pohl, Yingyao Zhou, et al.Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974Jun Liu, Shifeng Pan, Mindy H Hsieh, et al.Science (New York, N.Y.)|November 19, 2011
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discoveryStephan Meister, David M Plouffe, Kelli L Kuhen, et al.Cell Chemical Biology|July 8, 2025
Plasmodiumfalciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activityFlore Nardella, Tiantian Jiang, Lushun Wang, et al.Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.Cancer Discovery|April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET RearrangementsSeshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.Pageof 8